Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta
MSB11455
antidrug antibodies
immunogenicity
pegfilgrastim
safety
tolerability
Journal
Pharmacology research & perspectives
ISSN: 2052-1707
Titre abrégé: Pharmacol Res Perspect
Pays: United States
ID NLM: 101626369
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
16
12
2019
revised:
24
02
2020
accepted:
01
03
2020
entrez:
26
4
2020
pubmed:
26
4
2020
medline:
7
4
2021
Statut:
ppublish
Résumé
MSB11455 is a proposed biosimilar to the currently licensed reference pegfilgrastim (Neulasta
Identifiants
pubmed: 32333641
doi: 10.1002/prp2.578
pmc: PMC7183238
doi:
Substances chimiques
Antibodies
0
Biosimilar Pharmaceuticals
0
pegfilgrastim
3A58010674
Polyethylene Glycols
3WJQ0SDW1A
Filgrastim
PVI5M0M1GW
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e00578Informations de copyright
© 2020 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
Références
J Oncol Pharm Pract. 2016 Oct;22(5):702-16
pubmed: 26769697
Eur J Cancer. 2011 Jan;47(1):8-32
pubmed: 21095116
BMC Cancer. 2011 Sep 23;11:404
pubmed: 21943360
BioDrugs. 2009;23(3):175-86
pubmed: 19627169
Blood. 1996 Sep 15;88(6):1907-29
pubmed: 8822908
Pharmacol Res Perspect. 2020 Apr;8(2):e00578
pubmed: 32333641
Crit Rev Oncol Hematol. 2014 Jan;89(1):112-28
pubmed: 24041627
Biologicals. 2015 Sep;43(5):298-306
pubmed: 26144595
Biometrics. 1991 Dec;47(4):1399-408
pubmed: 1786325